Moracin BCAS# 67259-16-9 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 67259-16-9 | SDF | Download SDF |
PubChem ID | 5319887 | Appearance | Powder |
Formula | C16H14O5 | M.Wt | 286.28 |
Type of Compound | Phenols | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 2-(3-hydroxy-5-methoxyphenyl)-6-methoxy-1-benzofuran-5-ol | ||
SMILES | COC1=CC(=CC(=C1)O)C2=CC3=CC(=C(C=C3O2)OC)O | ||
Standard InChIKey | GOUSNRMGQRTROZ-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C16H14O5/c1-19-12-4-9(3-11(17)7-12)14-6-10-5-13(18)16(20-2)8-15(10)21-14/h3-8,17-18H,1-2H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Moracin B Dilution Calculator
Moracin B Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.4931 mL | 17.4654 mL | 34.9308 mL | 69.8617 mL | 87.3271 mL |
5 mM | 0.6986 mL | 3.4931 mL | 6.9862 mL | 13.9723 mL | 17.4654 mL |
10 mM | 0.3493 mL | 1.7465 mL | 3.4931 mL | 6.9862 mL | 8.7327 mL |
50 mM | 0.0699 mL | 0.3493 mL | 0.6986 mL | 1.3972 mL | 1.7465 mL |
100 mM | 0.0349 mL | 0.1747 mL | 0.3493 mL | 0.6986 mL | 0.8733 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Procumboside A
Catalog No.:BCX0467
CAS No.:850894-16-5
- Zataroside A
Catalog No.:BCX0466
CAS No.:95645-53-7
- 6β-Hydroxy-7-epi-α-cyperone
Catalog No.:BCX0465
CAS No.:6851-55-4
- Alpinenone
Catalog No.:BCX0464
CAS No.:103425-23-6
- 15-O-Ethylzerumin B
Catalog No.:BCX0463
CAS No.:1707019-00-8
- Monardin C
Catalog No.:BCX0462
CAS No.:1262796-93-9
- (E)-14-Hydroxy-15-norlabda-8(17),12-dien-16-al
Catalog No.:BCX0461
CAS No.:114370-19-3
- 6'-O-Glucopyranosylalbiflorin
Catalog No.:BCX0460
CAS No.:1001644-88-7
- Breynioside A
Catalog No.:BCX0459
CAS No.:63555-02-2
- Sanggenon M
Catalog No.:BCX0458
CAS No.:922080-11-0
- Sanggenon A
Catalog No.:BCX0457
CAS No.:76464-71-6
- Sanggenol G
Catalog No.:BCX0456
CAS No.:202526-52-1
- Sanggenol F
Catalog No.:BCX0469
CAS No.:202526-51-0
- 15-Hydroxylabda-8(17),12E-dien-16-al
Catalog No.:BCX0470
CAS No.:283614-59-5
- 6'-O-p-Hydroxybenzoylgastrodin
Catalog No.:BCX0471
CAS No.:1551525-70-2
- Mulberrofuran V
Catalog No.:BCX0472
CAS No.:174423-49-5
- Labda-8(17),12E,14-trien-16,15-olide
Catalog No.:BCX0473
CAS No.:917078-10-5
- Galanal B
Catalog No.:BCX0474
CAS No.:104113-52-2
- Methyl indole-3-acetate
Catalog No.:BCX0475
CAS No.:1912-33-0
- Rankinidine
Catalog No.:BCX0476
CAS No.:106466-66-4
- Sinapyl alcohol
Catalog No.:BCX0477
CAS No.:537-33-7
- Gypenoside LXXV
Catalog No.:BCX0478
CAS No.:110261-98-8
- Indole-3-acetic acid β-D-glucopyranosyl ester
Catalog No.:BCX0479
CAS No.:19817-95-9
- Schisanhenol B
Catalog No.:BCX0480
CAS No.:102681-52-7
Exploring the pharmacological components and effective mechanism of Mori Folium against periodontitis using network pharmacology and molecular docking.[Pubmed:35430443]
Arch Oral Biol. 2022 Jul;139:105391.
OBJECTIVES: To investigate the main active components, potential targets of action and analyze the potential molecular mechanisms of Mori Folium in preventing and treating periodontitis using network pharmacology and molecular docking methods. MATERIALS AND METHODS: The main components and action targets of Mori Folium were obtained in TCMSP and ETCM databases, and then the action targets of Mori Folium components were inversing screening using Swiss Target Prediction and BATMAN-TCM databases. Targets associated with periodontitis were retrieved from OMIM, Genecard, DrugBank, NCBI Gene and DisGeNET databases. Intersectional targets of Mori Folium and periodontitis were obtained by Venn analysis. Construction of an "active components-targets" network to prevent and treat periodontitis in Mori Folium using Cytoscape 3.8.0. The STRING database was used to construct the protein-protein interaction (PPI) network of intersecting targets, and the core network was screened using CytoNCA and MCODE plug-ins. Gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) enrichment analyses were performed using the ClusterProfile package of R software, and then the "Mori Folium active components-targets-signaling pathway" network was constructed using Cytoscape software. Molecular docking was performed using AutoDock Vina software, and Pymol and LigPlus visualized the results. RESULTS: Sixteen active components and 1048 targets were screened from Mori Folium, of which 164 were intersectional with periodontitis targets and were considered potential therapeutic targets. The "Mori Folium active components-action targets" network identified Quercetin, Moracin D, Moracin E, Moracin G, Moracin H and Moracin B as the main active ingredients of Mori Folium for the prevention and treatment of periodontitis. PPI network analysis revealed interleukin 6 (IL6), albumin (ALB), tumor necrosis factor (TNF), vascular endothelial growth factor A (VEGFA), RAC-alpha serine/threonine-protein kinase (AKT1), cellular tumor antigen p53 (TP53), prostaglandin G/H synthase 2 (PTGS2), pro-epidermal growth factor (EGF), matrix metalloproteinase 9 (MMP9) and interleukin 6 (IL10) as the top 10 core potential targets. GO and KEGG enrichment analyses showed that the action targets of Mori Folium against periodontitis were mainly related to the response to bacterium and their lipopolysaccharide, angiogenesis and reactive oxygen species metabolic process, as well as through signaling pathways that regulate processes related to the accumulation of advanced glycation end products (AGEs), response to oxidative stress, response to inflammatory, and osteoclast differentiation during the development of the disease. Molecular docking revealed that Quercetin, Moracin D, Moracin E, Moracin G, Moracin H and Moracin B were able to bind stably to AKT1, PTGS2 and ESR1 targets, with Moracin E showing the most stable structure after binding to AKT1. CONCLUSIONS: In conclusion, this study revealed the active components, potential targets of action and the potential molecular mechanisms and pharmacological activities involved in the prevention and treatment of periodontitis in Mori Folium, providing a reference for the development of drugs from Mori Folium for the prevention and treatment of periodontitis.
Isolation, Identification, and Quantification of Tyrosinase and alpha-Glucosidase Inhibitors from UVC-Irradiated Mulberry (Morus alba L.) Leaves.[Pubmed:31008101]
Prev Nutr Food Sci. 2019 Mar;24(1):84-94.
Methanol extracts from ultraviolet (UV) C-irradiated mulberry leaves (UVC-IML) exhibit stronger tyrosinase and alpha-glucosidase inhibitory activities than those from unirradiated mulberry leaves. Through a bioassay-guided fractionation and purification process, two oxyresveratrol derivatives, oxyresveratrol (ORT) and 4'-prenyloxyresveratrol (PORT), and six 2-arylbenzofuran derivatives [Moracin B (MCB), moracin C (MCC), moracin M (MCM), moracin N (MCN), 6,5'-dimethoxymoracin M (DMMCM), and chalcomoracin (CMC)] were isolated from the methanol extract from UVC-IML. Their chemical structures were determined by UV, mass, and nuclear magnetic resonance spectrometry. ORT and PORT showed potent tyrosinase inhibitory activities with the half maximal inhibitory concentration (IC(50)) values of 0.57 and 0.90 muM, respectively, and CMC exhibited significant tyrosinase and alpha-glucosidase inhibitory activity with IC(50) values of 5.61 and 6.00 muM, respectively. Levels of these eight compounds were increased significantly following irradiation compared with untreated mulberry leaves; ORTs increased approximately 4 fold and moracins increased 2~16 fold. These data suggest that UVC-IML may represent a promising source of nutraceuticals and cosmeceuticals for prevention of diabetes and skin aging.